FDA clears Regeneron gene therapy for OTOF-related hearing loss
Bottom line
CURRENT BRIEF VERSION: Regeneron has won U.S. FDA accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first approved gene therapy for a genetic form of hearing loss and the first dual AAV gene therapy cleared by the agency. The one-time treatment is indicated for pediatric and adult patients with severe-to-profound or profound sensorineural hearing loss tied to confirmed biallelic OTOF variants, with preserved outer hair cell function and no prior cochlear implant in the same ear. FDA said the decision was based on an ongoing single-arm trial in 24 pediatric patients, with 80% of the 20 evaluable patients showing improved hearing. Regeneron has also said it plans to provide the therapy at no cost to clinically eligible patients in the U.S., though administration-related costs may still apply. In the CHORD study, 10 children were treated in one ear and 10 in both ears, and enrollment of patients younger than 18 is ongoing across the U.S., UK, Spain, Germany, and Japan. (fda.gov)
Why it matters: For veterinary professionals, this isn’t a companion animal product story, but it is a signal worth watching. Otarmeni’s approval shows how far gene therapy platforms, inner-ear delivery techniques, and rare-disease regulatory pathways have advanced. Those same translational tools, including AAV-based delivery, surgery-linked administration, and accelerated approval built around surrogate endpoints, could shape future work in inherited neurologic, sensory, and rare diseases across animal health. It’s also a reminder that genetic diagnostics are becoming more actionable: when a molecular diagnosis can open the door to a targeted therapy, expectations around screening, referral, and specialty care tend to change. (fda.gov)
What to watch: FDA said continued approval may depend on longer-term data on durability, speech and quality-of-life outcomes, while Regeneron’s ongoing CHORD study remains a key source of follow-up evidence. Company-reported data add that 16 of 20 participants met the primary endpoint at 24 weeks, 70% met a key auditory brainstem response endpoint, all responders maintained benefit through 48 weeks, and 5 of 12 reached hearing levels in the normal range. (fda.gov)
CURRENT FULL VERSION: Regeneron’s Otarmeni approval is a milestone well beyond hearing care. On April 23, 2026, the U.S. FDA granted accelerated approval to the one-time gene therapy for OTOF-related severe-to-profound and profound sensorineural hearing loss, making it the first approved gene therapy for a genetic form of hearing loss and the first dual AAV vector-based gene therapy cleared by the agency. The treatment is delivered surgically into the cochlea, one dose per ear, using a biologic-device combination system. (fda.gov)
The background matters here. OTOF-related hearing loss is an ultra-rare condition that Regeneron says affects about 50 newborns a year in the U.S. The disorder stems from loss of functional otoferlin, a protein needed for signaling between inner ear sensory cells and the auditory nerve. Historically, care has centered on supportive technologies such as hearing devices or cochlear implantation rather than restoration of native auditory signaling. Otarmeni is designed to change that by delivering a functional copy of the OTOF gene directly to inner hair cells. (fda.gov)
FDA’s approval was based on an ongoing, multicenter, single-arm clinical trial in 24 pediatric patients ages 10 months to 16 years. Among the 20 patients evaluable for efficacy, 80% showed hearing improvement, which FDA said is not expected in the natural history of untreated disease. Regeneron’s release adds more detail from the pivotal CHORD study: 10 participants were treated in one ear and 10 in both ears, and enrollment of patients younger than 18 remains ongoing in the U.S., UK, Spain, Germany, and Japan. Sixteen of 20 participants met the primary endpoint at 24 weeks based on pure tone audiometry at a threshold of 70 dB HL or better, one additional participant reached that threshold by 48 weeks, and 14 of 20 met a key secondary endpoint on auditory brainstem response at 24 weeks. Among those followed to 48 weeks, all prior responders maintained benefit, with 5 of 12 reaching hearing levels in the normal range, including whisper-level sounds. (fda.gov)
The safety profile and delivery logistics are also notable. Common adverse events included middle ear infection, nausea, dizziness, vomiting, and procedural pain, with additional events such as gait disturbance and nystagmus reported in Regeneron’s summary. FDA said providers should monitor for surgical complications and noted the therapy is not recommended when anatomy prevents safe access to the inner ear. The label specifies use in patients with preserved outer hair cell function and no prior cochlear implant in the same ear, underscoring how tightly targeted this approval is. (fda.gov)
Industry reaction has focused on both the science and access. In Regeneron’s announcement, investigators described rapid and meaningful hearing responses in treated children, while advocacy leader Janet DesGeorges of Hands & Voices emphasized that families need balanced information and a range of options as genetic hearing-loss care evolves. Regeneron also said it will provide Otarmeni free of charge to clinically eligible U.S. patients, although hospitals, surgeons, anesthesia, and other administration-related costs may still fall outside that commitment. (globenewswire.com)
Why it matters: For veterinary professionals, the immediate clinical relevance is indirect, but the strategic relevance is real. Otarmeni is another example of human medicine moving from diagnosis of inherited disease to intervention at the gene level, using highly specific inclusion criteria, specialty delivery systems, and post-approval evidence generation. That matters for animal health because many of the same questions are already familiar in veterinary medicine: when to recommend genetic testing, how to counsel pet parents on inherited disease risk, what specialty infrastructure is needed for advanced therapeutics, and how cost, referral access, and procedural complexity may limit uptake even when the science works. The approval also highlights how regulators are willing to use accelerated pathways for rare conditions when surrogate or intermediate endpoints are reasonably likely to predict benefit. (fda.gov)
There’s also a translational lesson in the platform itself. AAV-based gene delivery, organ-specific administration, and narrow genotype-defined indications are becoming more established in human medicine. For veterinary stakeholders tracking the future of precision therapeutics, that’s relevant to inherited retinal disease, neurologic disorders, and other rare conditions in dogs and cats where molecular diagnosis may eventually pair with targeted intervention. The hurdle, as in human medicine, won’t just be efficacy. It will be manufacturing, surgical expertise, long-term follow-up, and who pays for treatment. This last point is especially visible here, given Regeneron’s unusual decision to offer the drug itself at no cost in the U.S. while leaving administration costs outside its direct control. (fda.gov)
What to watch: Continued approval will hinge on durability and confirmation that hearing gains translate into speech development and quality-of-life benefits, according to FDA. The ongoing CHORD trial will be central to that readout, and the approval may also draw attention because it came through FDA’s Commissioner’s National Priority Voucher framework, with a public FDA meeting on that pilot program scheduled for June 4, 2026. Longer follow-up will also clarify whether the early response pattern seen so far, including maintained benefit among responders through 48 weeks and normal-range hearing in a subset of children, holds up in a broader international cohort. (fda.gov)